Journey Medical (DERM) Insider Jayne Buys 10,000 Shares
Insider Toledano Miranda Jayne purchased 10,000 shares of Journey Medical Corporation.
Reviewed by automated data checks against the source filing. How we make and check alerts
Toledano Miranda Jayne bought 10,000 shares of Journey Medical Corporation ($DERM) on June 25, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $DERM is up 14.0% after 1 week, up 2.4% after 1 month and down 20.3% to date (from the $6.22 close on Jun 25, 2026).
DERM
Journey Medical Corporation
Key Points
- On June 25, 2026, Toledano Miranda Jayne acquired 10,000 shares of Journey Medical Corporation, trading on the NasdaqCM under the ticker DERM.
- Journey Medical Corporation, with a market cap of approximately $182.3 million, saw its shares trading near $6.62 on Tuesday.
- Multiple insiders, including CFO Joseph Benesch, have recently acquired shares, while analysts maintain a strong buy consensus with a target price of $13.5.
Get $DERM trade alerts by text
We text you when insiders, Congress or big funds trade $DERM. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Journey Medical Corporation alert may contain errors. Disclosures
Toledano Miranda Jayne recently purchased 10,000 shares of Journey Medical Corporation (NASDAQ: DERM) on June 25, 2026. This insider action comes amidst a series of similar transactions by other insiders at the company.
Insider Buying and Selling at Journey Medical Corporation
On June 25, 2026, several insiders, including Toledano Miranda Jayne, Justin Adam Smith, Michael Cooper Pearce, Neil Herskowitz, Lindsay MD Rosenwald, and CFO Joseph Benesch, acquired 10,000 shares each. These transactions were not part of any pre-planned trading programs, indicating a direct purchase of shares.
Journey Medical Corporation Stock Down 9.4%
Shares of Journey Medical Corporation traded near $6.62 on Tuesday. The company, operating in the healthcare sector, has a market cap of about $182.3 million. Despite not being profitable, its forward P/E ratio is listed as -110.3. The stock's 52-week range spans from $4.31 to $9.56, with a 50-day moving average of $5.79 and a 200-day moving average of $7.12. The company's current ratio stands at 1.72, with a quick ratio of 1.38 and a debt-to-equity ratio of 82.6.
Analysts Set New Price Targets
Analysts have shown optimism towards Journey Medical Corporation, with HC Wainwright & Co. reiterating a buy rating and a $13.0 price target on March 26, 2026. The consensus among analysts is a strong buy, with an average target price of $13.5 based on four analyst opinions.
About Journey Medical Corporation
Journey Medical Corporation is a Scottsdale, Arizona-based pharmaceutical company specializing in dermatological products. Founded in 2014, it focuses on developing and commercializing treatments for skin conditions. Its products include Qbrexza for hyperhidrosis, Accutane for severe acne, and Amzeeq for acne vulgaris, among others. Led by CEO Claude Maraoui, the company employs 58 people.
Bottom Line
The insider buying activity at Journey Medical Corporation, including the recent acquisition by Toledano Miranda Jayne, suggests confidence among its executives. Journey Medical operates in the competitive field of dermatological pharmaceuticals, and its stock has seen varied analyst ratings. Investors often track insider transactions for potential insights, but it's important to note these actions do not guarantee future performance.
Related Filing Alerts
Source: Toledano Miranda Jayne's Form 4 filing on $DERM (Jun 25, 2026). Find the original filing: DERM Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts